drugset / Trial / NCT00204594

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

NCT00204594

Phase 1/2 Completed 1 enrolled University Hospital Tuebingen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis.

Timeline

Start
2005-10
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous PBMCs Cell therapy Other
Subject rM28 Unknown Other

Indications